R
RetiSpec
RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer’s disease biomarkers in the eye
About RetiSpec
RetiSpec is a medical imaging company focused on the early detection of disease biomarkers in the eye, particularly for Alzheimer's disease. The company operates in the healthcare and medical technology market, serving clinics, hospitals, and research institutions. RetiSpec's core product is a retinal scanner that integrates both software and hardware components, which can be applied to existing retinal cameras commonly found in medical offices. The technology uses computer vision and machine learning algorithms to detect unique signatures of biomarkers within seconds, enabling timely and specific therapeutic interventions. This early detection tool aims to slow or even prevent the progression of diseases, thereby improving patient outcomes and reducing healthcare costs. RetiSpec generates revenue through the sale and licensing of its retinal scanning technology to medical facilities and research organizations. The company also collaborates with partners for clinical studies and further development of its technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Canada
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 43.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Neurology, Mental Health, Alzheimers Disease, Degenerative Diseases, Non-Invasive medical devices and treatments, Spinout, Clinical Decision Support
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Computer Vision
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2024 | $10M | $40M | Eli Lilly · Topcon Healthcare · GENTEX · Verge HealthTech Fund | ↗ |
| EARLY VC✓Equity / VC | May 2024 | $0 | — | Topcon Healthcare | ↗ |
Growth signals
Latest recorded traffic for RetiSpec is 480 monthly website visits, down 34.2% over the last three months. RetiSpec's team grew 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Ontario Brain Institute
Center of Aging and Brain Health Innovation
Series A7 investors entered at this stage
Topcon Healthcare
IGan Partners
Eli Lilly
GENTEX
Verge HealthTech Fund
University of Minnesota Twin Cities
Alzheimer's Drug Discovery Foundation
Other known investors3 additional known investors
MassChallenge
Berkeley SkyDeck Accelerator- DCDiscovery Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RetiSpec on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RetiSpec’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.